Eligible patients may receive FDA-approved GLP-1 medications through the Medicare GLP-1 Bridge Program or affordable compounded GLP-1 medications, with ongoing provider support
[16] Hepatotoxicity (e.g., fatty liver, cholestasis, hepatitis, and hepatic necrosis) has been reported with tamoxifen use
The provider includes documentation supporting medical necessity, such as a confirmed diagnosis of type 2 diabetes, recent A1c results, and a history of prior treatment
While and cyclodextrins contain either a smaller or larger cavity diameter compared to the drugs ready for inclusion, cyclodextrins allow the inclusion of a number of drugs [2]
The monthly list price of semaglutide-based treatments in the US is about between $900 and $1,000, which supports their status as a high-value, specialized treatment.18][19]
Materials and M ethods This study included 90 type 2 diabetic subjects (both genders aged 30-60 years) , identified with type 2 diabetes mellitus in Thumbay University Hospital and Clinics, collaborated with Thumbay Labs, Ajman, United Arab Emirates
.png)
